Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin–protein ligase with monoubiquitylation capacity
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Mutations in the parkin gene, encoding an E3 ubiquitin-protein ligase, are a frequent cause of autosomal recessive parkinsonism and are also involved in sporadic Parkinson's disease. Loss of Parkin function is thought to compromise the polyubiquitylation and proteasomal degradation of specific substrates, leading to their deleterious accumulation. Several studies have analyzed the effects of parkin gene mutations on the biochemical properties of the protein. However, the absence of a cell-free system for studying intrinsic Parkin activity has limited the interpretation of these studies. Here we describe the biochemical characterization of Parkin and 10 pathogenic variants carrying amino-acid substitutions throughout the sequence. Mutations in the RING fingers or the ubiquitin-like domain decreased the solubility of the protein in detergent and increased its tendency to form visible aggregates. None of the mutations studied compromised the binding of Parkin to a series of known protein partners/substrates. Moreover, only two variants with substitutions of conserved cysteine residues of the second RING finger were inactive in a purely in vitro ubiquitylation assay, demonstrating that loss of ligase activity is a minor pathogenic mechanism. Interestingly, in this in vitro assay, Parkin catalyzed the linkage of single ubiquitin molecules only, whereas the ubiquitin-protein ligases CHIP and Mdm2 promoted the formation of polyubiquitin chains. Similarly, in mammalian cells Parkin promoted the multimonoubiquitylation of its substrate p38, rather than its polyubiquitylation. Thus, Parkin may mediate polyubiquitylation or proteasome-independent monoubiquitylation depending on the protein context. The discovery of monoubiquitylated Parkin species in cells hints at a novel post-translational modification potentially involved in the regulation of Parkin function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024 · cited 5×
“concluded that it promoted the ubiquitylation of synphilin or p38 even more efficiently than normal Parkin (26,32,40,48).”
BackgroundResultInfluentialShimura, H., Schlossmacher, M. G., Hattori, N., Frosch, M. P., Trockenbacher, A., Schneider, R., Mizuno, Y., Kosik, K. S., & Selkoe, D. J. (2001) · Science · doi:10.1126/science.1060627 · Cited by 1,053
Zhang, Y., Gao, J., Chung, K. K. K., Huang, H., Dawson, V. L., & Dawson, T. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.240347797 · Cited by 982
de Rijk, M. C., Tzourio, C., Breteler, M. M., Dartigues, J. F., Amaducci, L., Lopez-Pousa, S., Manubens-Bertran, J. M., Alperovitch, A., & Rocca, W. A. (1997) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.62.1.10 · Cited by 833 · cited 1×
“Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease, affecting nearly 2% of individuals over the age of 65 (1).”
BackgroundChung, K. K. K., Zhang, Y., Lim, K. L., Tanaka, Y., Huang, H., Gao, J., Ross, C. A., Dawson, V. L., & Dawson, T. M. (2001) · Nature Medicine · doi:10.1038/nm1001-1144 · Cited by 750 · cited 4×
“However, in other cases, mutations had little or no effect on the interactions between Parkin and selected proteins (32,42,43,48,59,60,63,64).”
BackgroundResultInfluentialGenetic screening for a single common LRRK2 mutation in familial Parkinson's disease
Nichols, W. C., Pankratz, N., Hernandez, D., Paisán-Ruíz, C., Jain, S., Halter, C. A., Michaels, V. E., Reed, T., Rudolph, A., Shults, C. W., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17828-3 · Cited by 457
Cited by
PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1
Geisler, S., Holmström, K. M., Skujat, D., Fiesel, F. C., Rothfuss, O. C., Kahle, P. J., & Springer, W. (2010) · Nature Cell Biology · doi:10.1038/ncb2012 · Cited by 2,835
“First, insoluble Parkin mutations such as C212Y, C289G, C418R and C441R affected structurally important residues, disrupted proper folding of the RING motifs and thus formed inclusions per se”
BackgroundMatsuda, N., Sato, S., Shiba, K., Okatsu, K., Saisho, K., Gautier, C. A., Sou, Y.-S., Saiki, S., Kawajiri, S., Sato, F., et al. (2010) · Journal of Cell Biology · doi:10.1083/jcb.200910140 · Cited by 1,969
“In vitro experiments have previously shown that two of the mutations (T415N and G430D) in the RING2 domain abolish E3 activity of Parkin, whereas E3 activity is unaffected by the other mutations (Hampe et al., 2006; Matsuda et al., 2006).”
BackgroundMitochondrial dysfunction and oxidative stress in Parkinson's disease
Subramaniam, S. R., & Chesselet, M.-F. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.04.004 · Cited by 913
Drosophila Parkin requires PINK1 for mitochondrial translocation and ubiquitinates Mitofusin
Ziviani, E., Tao, R. N., & Whitworth, A. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913485107 · Cited by 735
Mitochondrial dysfunction in Parkinson's disease
Winklhofer, K. F., & Haass, C. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.013 · Cited by 688
What Genetics Tells us About the Causes and Mechanisms of Parkinson's Disease
Corti, O., Lesage, S., & Brice, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00022.2010 · Cited by 611
Self-citationPINK1/PARKIN signalling in neurodegeneration and neuroinflammation
Quinn, P. M. J., Moreira, P. I., Ambrósio, A. F., & Alves, C. H. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01062-w · Cited by 481
Veeriah, S., Taylor, B. S., Meng, S., Fang, F., Yilmaz, E., Vivanco, I., Janakiraman, M., Schultz, N., Hanrahan, A. J., Pao, W., et al. (2010) · Nature Genetics · doi:10.1038/ng.491 · Cited by 406
The two faces of protein misfolding: gain‐ and loss‐of‐function in neurodegenerative diseases
Winklhofer, K. F., Tatzelt, J., & Haass, C. (2008) · The EMBO Journal · doi:10.1038/sj.emboj.7601930 · Cited by 401
p62/SQSTM1 cooperates with Parkin for perinuclear clustering of depolarized mitochondria
Okatsu, K., Saisho, K., Shimanuki, M., Nakada, K., Shitara, H., Sou, Y., Kimura, M., Sato, S., Hattori, N., Komatsu, M., et al. (2010) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01426.x · Cited by 397
“…(i.e., the MBP moiety of the MBP-fused Parkin in vitro and the GFP moiety of the GFP-Parkin in cell) was intact in these Parkin mutations (Hampe et al. 2006; Matsuda et al. Genes to Cells (2010) 15, 887–900 2010 The Authors Journal compilation 2010 by the Molecular Biology Society of…”
BackgroundThe role of parkin in familial and sporadic Parkinson's disease
Dawson, T. M., & Dawson, V. L. (2010) · Movement Disorders · doi:10.1002/mds.22798 · Cited by 392
Autoregulation of Parkin activity through its ubiquitin‐like domain
Chaugule, V. K., Burchell, L., Barber, K. R., Sidhu, A., Leslie, S. J., Shaw, G. S., & Walden, H. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.204 · Cited by 339
“…EMBO Journal (2011) 30, 2853–2867 | & 2011 European Molecular Biology Organization | All Rights Reserved 0261-4189/11 www.embojournal.org &2011 European Molecular Biology Organization The EMBO Journal VOL 30 | NO 14 | 2011 EMBO THE JOURNAL 2853 et al, 2005; Hampe et al, 2006; Schlehe et al, 2008).”
BackgroundResultOlzmann, J. A., Li, L., Chudaev, M. V., Chen, J., Perez, F. A., Palmiter, R. D., & Chin, L.-S. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200611128 · Cited by 339
Structure of the human Parkin ligase domain in an autoinhibited state
Wauer, T., & Komander, D. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.125 · Cited by 328
The deubiquitinase USP15 antagonizes Parkin-mediated mitochondrial ubiquitination and mitophagy
Cornelissen, T., Haddad, D., Wauters, F., Van Humbeeck, C., Mandemakers, W., Koentjoro, B., Sue, C., Gevaert, K., De Strooper, B., Verstreken, P., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu244 · Cited by 327
RBR E3 ubiquitin ligases: new structures, new insights, new questions
Spratt, D. E., Walden, H., & Shaw, G. S. (2014) · Biochemical Journal · doi:10.1042/bj20140006 · Cited by 315
Deciphering the role of heterozygous mutations in genes associated with parkinsonism
Klein, C., Lohmann-Hedrich, K., Rogaeva, E., Schlossmacher, M. G., & Lang, A. E. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70174-6 · Cited by 309
Parkin Interacts with Ambra1 to Induce Mitophagy
Van Humbeeck, C., Cornelissen, T., Hofkens, H., Mandemakers, W., Gevaert, K., De Strooper, B., & Vandenberghe, W. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.1917-11.2011 · Cited by 287
Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease
Dodson, M. W., & Guo, M. (2007) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2007.04.010 · Cited by 278
PINK1 drives Parkin self-association and HECT-like E3 activity upstream of mitochondrial binding
Lazarou, M., Narendra, D. P., Jin, S. M., Tekle, E., Banerjee, S., & Youle, R. J. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201210111 · Cited by 236
Parkin-catalyzed Ubiquitin-Ester Transfer Is Triggered by PINK1-dependent Phosphorylation
Iguchi, M., Kujuro, Y., Okatsu, K., Koyano, F., Kosako, H., Kimura, M., Suzuki, N., Uchiyama, S., Tanaka, K., & Matsuda, N. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.467530 · Cited by 209
Nedd4-2 Catalyzes Ubiquitination and Degradation of Cell Surface ENaC
Zhou, R., Patel, S. V., & Snyder, P. M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611329200 · Cited by 188
Cookson, M. R. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009415 · Cited by 170
“Specifically, most studies of wild-type or mutant parkin reported cytosolic and nuclear localization (Cookson et al. 2003; Sriram et al. 2005; Hampe et al. 2006), although some studies noted a small mitochondrial pool of the protein (Darios et al. 2003; Kuroda et al. 2006).”
BackgroundFiesel, F. C., Caulfield, T. R., Moussaud-Lamodière, E. L., Ogaki, K., Dourado, D. F. A. R., Flores, S. C., Ross, O. A., & Springer, W. (2015) · Human Mutation · doi:10.1002/humu.22808 · Cited by 89
“While earlier systematic reports from the premitophagy era potentially analyzed Parkin in an autoinhibited conformation [Sriram et al., 2005; Hampe et al., 2006; Matsuda et al., 2006], more recent in vitro studies were designed to incorporate functional PINK1 as an important activator of Parkin…”
BackgroundMethodMitochondrial Dynamics and Parkinson's Disease: Focus on Parkin
Lim, K.-L., Ng, X.-H., Grace, L. G.-Y., & Yao, T.-P. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4105 · Cited by 64
A mutational atlas for Parkin proteostasis
Clausen, L., Voutsinos, V., Cagiada, M., Johansson, K. E., Grønbæk-Thygesen, M., Nariya, S., Powell, R. L., Have, M. K. N., Oestergaard, V. H., Stein, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45829-4 · Cited by 51
Moussa, C. E.-H. (2015) · Neurodegenerative Diseases · doi:10.1159/000430888 · Cited by 13
Metadata
- Authors
- Hampe, C., Ardila-Osorio, H., Fournier, M., Brice, A., & Corti, O.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-05-19
- Volume
- 15
- Issue
- 13
- Pages
- 2059-2075
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2150157946
- Cited by
- 226
- References
- 7
- FWCI
- 12.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.